🔗 Share this article WHO Issues Concern Over Severe Scarcity of Obesity Jabs Fewer than a tenth of patients eligible to benefit from weight-loss injections like Wegovy can access them, states the global health agency as it publishes its inaugural recommendations on the drugs. With over a billion people worldwide now obese, it is calling for more widespread and fairer availability to GLP-1 medication. Per forecasts, more than two billion will be living with obesity by 2030 unless action is taken. "Our new guidance recognises that excess weight is a lifelong illness that can be addressed with comprehensive and lifelong support," said WHO director-general Tedros Adhanom Ghebreyesus. Substantial prices, limited production capacity, and distribution challenges are significant hurdles to universal availability to the treatments that can assist patients in reducing substantial body mass, notes the body. GLP-1 Therapy Supply Crisis Despite the current best projected case, the manufacturing of such drugs would only suffice for approximately 100 million people – less than 10% of the global need, per the WHO. The advice urges countries and companies to increase access, by measures including voluntary licensing. A patent on a key compound – the primary ingredient of the drug Wegovy – is scheduled to end in multiple countries in 2026. How Obesity Jabs Operate GLP-1 drugs mimick a biological compound to slow digestion, reduce hunger and boost feelings of fullness so people eat less. Patients typically start to lose weight within a few weeks of starting on the once-weekly jabs. Studies points to people may regain a significant portion after a year of halting the treatment, because their normal hunger come back. Being carrying excess weight elevates your chance for experiencing medical conditions, including diabetes, heart disease, brain attack, and certain malignancies. Excess weight affects people in all nations and was linked to 3.7 million deaths worldwide in 2024, according to the health agency.
Fewer than a tenth of patients eligible to benefit from weight-loss injections like Wegovy can access them, states the global health agency as it publishes its inaugural recommendations on the drugs. With over a billion people worldwide now obese, it is calling for more widespread and fairer availability to GLP-1 medication. Per forecasts, more than two billion will be living with obesity by 2030 unless action is taken. "Our new guidance recognises that excess weight is a lifelong illness that can be addressed with comprehensive and lifelong support," said WHO director-general Tedros Adhanom Ghebreyesus. Substantial prices, limited production capacity, and distribution challenges are significant hurdles to universal availability to the treatments that can assist patients in reducing substantial body mass, notes the body. GLP-1 Therapy Supply Crisis Despite the current best projected case, the manufacturing of such drugs would only suffice for approximately 100 million people – less than 10% of the global need, per the WHO. The advice urges countries and companies to increase access, by measures including voluntary licensing. A patent on a key compound – the primary ingredient of the drug Wegovy – is scheduled to end in multiple countries in 2026. How Obesity Jabs Operate GLP-1 drugs mimick a biological compound to slow digestion, reduce hunger and boost feelings of fullness so people eat less. Patients typically start to lose weight within a few weeks of starting on the once-weekly jabs. Studies points to people may regain a significant portion after a year of halting the treatment, because their normal hunger come back. Being carrying excess weight elevates your chance for experiencing medical conditions, including diabetes, heart disease, brain attack, and certain malignancies. Excess weight affects people in all nations and was linked to 3.7 million deaths worldwide in 2024, according to the health agency.